RecruitingNCT01047865

Type 1 Diabetes Recurrence in Pancreas Transplants

Recurrence of T1D in Pancreas Transplantation

Sponsor

University of Miami

Enrollment

400 participants

Start Date

May 1, 2005

Study Type

OBSERVATIONAL

Conditions

Diabetes Mellitus, Type 1

Summary

The hypothesis is that humoral and cellular islet-specific responses are an early risk factor for recurrence of autoimmunity and hyperglycemia in simultaneous pancreas-kidney (SPK) recipients independent of alloimmunity. This study will test the hypothesis and will assess their individual and combined predictive value.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study follows patients who received both a pancreas and kidney transplant at the same time to understand whether Type 1 diabetes can come back in the transplanted pancreas. **You may be eligible if...** - You are between 18 and 75 years old - You have received a simultaneous pancreas and kidney transplant (from either a living or deceased donor) - You have signed consent and are willing to be followed for up to 24 months **You may NOT be eligible if...** - You have received any organ transplant other than a pancreas-kidney combination Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

University of Miami Miller School of Medicine Transplant Clinic

Miami, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT01047865

Related Trials

The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France

NCT0721112621 locations

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

NCT0633413358 locations

Gemini Study: A Prospective, Multicenter Evaluation of Performance and Safety of the Eversense Gemini System With Flash Glucose Measurement Feature

NCT073863401 location

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

NCT07222332132 locations

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

NCT07222137107 locations